Wells Fargo’s Damora Therapeutics DMRA Stock Holding History

Wells Fargo’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	+47,458	New	+$1.15M	﹤0.01%	3960
2024 Q2	–	Sell	-6	Closed	-$121	–	7112
2024 Q1	$121	Hold	6	–	–	﹤0.01%	6609
2023 Q4	$109	Sell	6 -13	-68%	-$200	﹤0.01%	6747
2023 Q3	$341	Sell	19 -81	-81%	-$3.18K	﹤0.01%	6443
2023 Q2	$6.31K	Hold	100	–	–	﹤0.01%	6036
2023 Q1	$4.97K	Hold	100	–	–	﹤0.01%	6057
2022 Q4	$2.87K	Sell	100 -20	-17%	-$830	﹤0.01%	5917
2022 Q3	$5K	Buy	120 +1	+0.8%	+$51	﹤0.01%	5900
2022 Q2	$5K	Hold	119	–	–	﹤0.01%	6003
2022 Q1	$6K	Hold	119	–	–	﹤0.01%	6419
2021 Q4	$9K	Sell	119 -287	-71%	-$22.5K	﹤0.01%	6577
2021 Q3	$36K	Sell	406 -1,396	-77%	-$149K	﹤0.01%	5746
2021 Q2	$228K	Buy	1,802 +1,800	+90,000%	+$245K	﹤0.01%	4971
2021 Q1	$0	Buy	+2	New	+$544	﹤0.01%	7048

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Wells Fargo's DMRA Position: Q2 2026 in Review

Wells Fargo opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 47,458 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #3960 among its holdings. This is a return to the name: Wells Fargo previously reported a position in DMRA as recently as Q1 2024.

Wells Fargo first reported a position in DMRA in Q1 2021 and has held it in 14 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Wells Fargo held 47,458 shares of Damora Therapeutics worth $1.23M as of Q2 2026.
Damora Therapeutics was a new Wells Fargo position in Q2 2026.
Damora Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3960 holding.
Wells Fargo first reported a position in Damora Therapeutics in Q1 2021 and has held it in 14 quarters since.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.